Juvisé Pharmaceuticals Reports the Acquisition of Actelion’s Ponvory (ponesimod) for the Treatment of Multiple Sclerosis (MS)
Shots:
- Juvisé acquired the rights to Ponvory from Actelion Pharmaceutical (Johnson & Johnson) for its global commercialization, excluding the US & Canada , for the 1L treatment of adults with active forms of relapsing multiple sclerosis (RMS)
- While the financial details remain undisclosed, the acquisition was funded by a series of capital increases, additional debt, shareholder loans & the acquisition of minority stakes in Juvisé by Bpifrance & Pemberton
- Ponvory has shown superior efficacy results vs teriflunomide under P-III (OPTIMUM) clinical evaluation of adult patients with active RMS & has also shown a 30.5% reduction in Annualized Relapse Rate (1EP) & a significant reduction in MRI activity & fatigue (2EPs)
Ref: Businesswire | Image: Actelion
Related News:- Vanda Pharmaceuticals to Acquire the US and Canadian Rights for Ponvory from Actelion to Treat Relapsing Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
